Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taibowei® Adalimumab in Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
NCT07564505Phase 4Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in Crohn's disease, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07564505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564505.